Le réseau Unicancer représenté au congrès de l’ASCO 2019

 

Le réseau Unicancer est à nouveau représenté au congrès de l’ASCO, le rendez-vous de la communauté internationale des cancérologues, du 31 mai au 4 juin 2019 à Chicago. Les résultats des études promues par Unicancer ont été présentées via différentes présentations orales et des posters. 

 

Oral

Prediction of Treatment (tx)-Induced Fatigue in Breast Cancer (BC) patients (pts) using Machine Learning on  Genome Wide Association (GWAS) Data in the prospective CANTO cohort.

Group : UCBG

Study : CANTO

Authors : Sangkyu Lee, Joseph O. Deasy, Jung Hun Oh, Antonio Di Meglio, Sandrine Boyault, Marina Rousseau,  Céline Besse, Emilie Thomas,  Anne Boland, Paul Cottu, Olivier Tredan, Christelle Levy, Anne-Laure Martin, Sibille Everhard, Patti Ganz, Ann Partridge, Stefan Michiels, Jean-François Deleuze , Fabrice Andre, Ines Vaz Luis.

See the press release

TAXOMET trial  : prospective, randomized, multi-center trial in which non-diabetic men with metastatic castration-resistant prostate cancer (mCRPC) were randomized to treatment in either.

Study : TAXOMET

Authors : Jean Marc FERRERO, et al.

See the press release

 

Posters 

A GINECO randomized phase II assessing addition of an aromatase inhibitor to oral vinorelbine in pretreated metastatic breast cancer patients.

Study : CHEOPS

Authors : Pierre Heudel, et al.

 

NISCAHN: A Phase II, multicenter nonrandomized trial aiming at evaluating Nivolumab (N) in two cohorts of patients (pts) with recurrent/metastatic (R/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the Unicancer Head & Neck Group. Jérôme Fayette, MD, PhD – First Author  Centre Léon Bérard, Medical Oncology.

Group : UCH&N

Study : NISCAHN

Authors : Jérôme Fayette, et al.

 

MEDIPLEX : A phase 1 study of durvalumab (D) combined with pexidartinib (P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC).

Study : MEDIPLEX

Authors : Philippe Cassier, et al.

 

Improved local relapse-free and overall survival with secondary surgery after a first R1 or R2 resection in soft tissue sarcoma (STS) of the limbs or trunk wall: An analysis 10,931 patients (pts) in NETSARC.

Study : NETSARC

Authors : François Gouin, et al.

 

Results of the VENUS study: Bevacizumab efficacy and safety in platinum-sensitive recurrent ovarian cancer (OC) : A real-life ambispective study.

Study : VENUS

Authors : Isabelle Ray-Coquard

 

ALBAN: An open label, randomized, phase III trial, evaluating efficacy of atezolizumab in addition to one year BCG (bacillus Calmette-Guerin) bladder instillation in BCG-naive patients with high-risk nonmuscle invasive bladder cancer (AFU-GETUG 37). 

Group : GETUG

Study : ALBAN

Authors : Morgan Roupret, Yann Neuzillet, Aurelie Bertaut, Geraldine Pignot, Nadine Houede, Stephane Champiat, Soazig Nénan-Le Ficher, Maggy Chausson, Yohann Loriot.

 

Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for metastatic free survival (MFS) after radical prostatectomy (RP): Update at 9 years of the GETUG-AFU 16 phase III randomized trial (NCT00423475).

Group : GETUG

Study : GETUG16

Authors : Christian Carrie, Nicolas Magné, Patricia Burban-Provost, Paul Sargos, Igor Latorzeff, Stephane Supiot, Yazid Belkacemi, Didier Peiffert, Nedla Allouache, Bernard M. Dubray, Stephanie Servagi Vernat, Jean-Philippe Suchaud, Gilles Crehange, Stéphane Guerif, Meryem Brihoum, Nicolas Barbier, Pierre Graff-Cailleaud, Alain Ruffion, Sylvie Chabaud.

 

RUBY : a phase II study testing rucaparib in patients presenting a metastatic breast cancer (mBC) with Homologous Recombination Deficiency (HRD), without germline (g)BRCA mutation?

Group : Médecine personnalisée

Study : RUBY

Authors : A. Patsouris, O. Tredan, D. Nenciu, A. Tran-Dien, L.Campion, A. Gonçalves, M. Arnedos, MP. Sablin, W. Gouraud, M. Jimenez, N. Droin, , I. Bieche, C. Callens, A.Loehr, C. Vicier, F. André.

 

mTORC1 activation assessed in metastatic sample predicts outcome in patients with metastatic breast cancer treated with everolimus-exemestan: results from the SAFIRTOR study

Group : Médecine personnalisée

Study : EXPRESS

Authors : Le Saux O, Italiano A, Spaeth D, Heudel PE, Filleron T, Albiges L, , Bachelot T, Gonçalves A, Pierga J-Y, Barlesi F, Boige V, Lebbé C, Mortier L, Frenel JS, Tredan O Jimenez M, Legrand F, Ferte C .

 

High temporal variability of clinical side effects with and without adjuvant chemotherapy in 4684 early breast cancer patients in the CANTO trial.

Group : UCBG

Study : CANTO

Authors : Paul Cottu, Marie-Laure Tanguy,Enora Laas, Olivier Tredan , Sylvie GIACCHETTI, Sophie  GUILLERMET, Jean-Marc FERRERO, Olivier RIGAL, Carole TARPIN, Mario CAMPONE , Christelle LEVY, Patrick SOULIE, Laurence VANLEMMENS, Marion FOURNIER, Christelle JOUANNAUD, Sibille Everhard,  Jerome Lemonnier, Patrick Arveux, Ines Vaz Luis, Fabrice André.

 

Cognitive impairment in breast cancer patients before surgery ? Results of a subgroup of the French CANTO cohort.

Group : UCBG

Study : CANTO

Authors : M. Lange, I. Léger, O. Rigal,  I. Licaj, S. Rajpar, J. Le Fel, C. Lévy, A. Capel, I. Vaz Luis, J. Meyer, F. Lerebours, J. Pettrucci, L. Vanlemmens, M. Brion, A.L. Martin, C. Mesleard, P. Arveux, F. André, S. Dauchy, F. Joly. 

 

Impact of overweight, obesity and post-treatment weight changes on occupational reintegration of breast cancer (BC) survivors.

Group : UCBG

Study : CANTO

Authors : Antonio Di Meglio , Gwenn Menvielle, Agnes Dumas, Arnauld Gbenou, Thomas Bovagnet, Elise Martin, Arlindo R Ferreira (1), Laurence Vanlemmens (3) , Olivier Arsene (4), Mahmoud Ibrahim (5), Johanna Wassermann (6), Anne-Laure Martin (7), Jerome Lemonnier (7),  Lucia Del Mastro (8), Lee W Jones (9), Ann Partridge (10), Jennifer A Ligibel (10) , Fabrice Andre (1), Stefan Michiels (1), Ines Vaz-Luis.

 

Return to work after breast cancer : comprehensive longitudinal analyses of its determinants.

mTORC1 activation assessed in metastatic sample to predict outcome in patients with metastatic breast cancer treated with everolimus-exemestan: Results from the SAFIRTOR study.

Group : Médecine personnalisée

Study : SAFIR-TOR

Authors : T. Bachelot, I. Treilleux, C. Schiffler, I. Bieche, M. Campone, A.Patsouris, M. Arnedos, P. Cottu, JP. Jacquin, F Dalenc. V. Attignon, E. Rouleau, A. Morel, F. Legrand, M. Jimenez, F. Andre.

 

Multimodality liquid biopsy for early monitoring and outcome prediction in first line metastatic HER2 negative breast cancer: final results of the prospective cohort from the French Breast Cancer InterGroup Unicancer (UCBG): COMET study.

Group : UCBG

Study : GRT02-COMET

Authors : Jean-Yves Pierga, Amanda Silveira, Olivier Tredan, Marie-Laure Tanguy, Veronique Lorgis, Coraline Dubot, William Jacot, Anthony Goncalves, Marc Debled, Christelle Levy, Jean-Marc Ferrero, Christelle Jouannaud, Marie-Ange Mouret-Reynier, Florence Dalenc, Jérôme Lemonnier, Frederique Berger, Charlotte Proudhon, Francois Clement Bidard.

 

Differential impact of endocrine therapy (ET) and chemotherapy (CT) on quality of life (QoL) of 4262 breast cancer (BC) survivors: a prospective patient reported outcomes (PRO) analysis.

Group : UCBG

Study : CANTO

Authors : Arlindo R. Ferreira, Antonio Di Meglio, Barbara Pistilli, Arnauld Gbenou, Mayssam El-Mouhebb, Patricia A. Ganz, Ann H. Partridge, Suzette Delaloge, Charles Coutant, Paul-Henri Cottu, Florence Lerebours, Thierry Petit, Florence Dalenc, Philippe Rouanet, Antoine Arnaud, Anne-Laure Martin, Sibille Everhard, Stefan Michiels, Fabrice André, Ines Vaz-Luis.